【摘要】 目的观察喹硫平与利培酮治疗躁狂症的效果。方法选取2014年5月~2015年7月中国医科大学附属第一医院心理科收治的90例躁狂症患者。按照随机数字表法将患者分为观察组(n=45)和对照组(n=45)。观察组患者给予喹硫平(起始剂量为25 mg/次,2次/d,每隔1~3 d每次增加25 mg,逐渐增至治疗剂量300~600 mg/d,分2~3次服用。7 d为1个疗程,共4个疗程)联合碳酸锂(治疗初期0.5 g/d,3~7 d内加至每天1.0~1.5 g)进行治疗。对照组患者给予利培酮(起始剂量1~2 mg/次,1次/d,剂量可根据个体需要进行调整。剂量增加的幅度为1~2 mg/d,剂量增加至少隔日或间隔更多天数进行。7 d为1个疗程,共4个疗程)联合碳酸锂进行治疗。比较两组患者疗效、Bech-Rafaelsen躁狂量表(BRMS)评分、阳性与阴性症状量表(PANSS)评分、不良反应情况。结果治疗后观察组总有效率(95.56%)显著高于对照组(75.56%),差异有统计学意义(P<0.05)。两组治疗后1个月及2个月BRMS评分均较治疗前显著下降,差异有统计学意义(P<0.05),且两组治疗后1个月及2个月BRMS评分比较,差异有统计学意义(P<0.05)。两组治疗后1个月及2个月PANSS评分均较治疗前显著下降,差异有统计学意义(P<0.05),且两组治疗后1个月及2个月PANSS评分比较,差异有统计学意义(P<0.05)。观察组不良反应发生率(6.67%)显著低于对照组(42.22%),差异有统计学意义(P<0.05)。结论喹硫平治疗狂躁症的效果显著优于利培酮,且能有效降低患者不良反应发生率,具有较高的安全性。更多还原

【Abstract】 Objective To observe the effects of Quetiapine and Risperidone in the treatment of mania. Methods Ninety patients with mania admitted to the First Hospital of China Medical University from May 2014 to July 2015 were selected. The patients were randomly divided into observation group(n = 45) and control group(n = 45) by random number table method. The observation group was treated by Quetiapine(the starting dose was once 25 mg, 2 times a day,adding 25 mg for one time every 1-3 days, adding to 300-600 mg/d gradually, 2-3 times daily. 7 days was a course of treatment, total for 4 courses) combined with Lithium Carbonate(0.5 g/d for early treatment, adding to 1.0-1.5 g per day during 3-7 days). The control group was treated by Risperidone(the starting dose was 1-2 mg per time, once a day, the dose can be adjusted according to individual needs. The increasing range of dose was 1-2 mg/d, dose increasing should be taken every other day or interval for more days. 7 days was a course of treatment, total for 4 courses)combined with Lithium Carbonate. The clinical efficacy, Bech-Rafaelsen mania rating scale(BRMS), positive and negative syndrome scale(PANSS) score, adverse reactions between the two groups were compared. Results After treatment,the total effective rate of observation group(95.56%) was higher than that of control group(75.56%), there was a statistically significant difference(P < 0.05). The BRMS scores after treatment for one month and two months in the two groups were all decreased compared with those before treatment, the differences were statistically significant(P < 0.05),and there were statistically significant differences of BRMS scores after treatment for one month and two months between the two groups(P < 0.05). The PANSS scores after treatment for one month and two months in the two groups were all decreased compared with those before treatment, the differences were statistically significant(P < 0.05), and there were statistically significant differences of PANSS scores after treatment for one month and two months between the two groups(P < 0.05). The incidence rate of adverse reactions of observation group(6.67%) was lower than that of control group(42.22%), there was a statistically significant difference(P < 0.05). Conclusion The therapeutic effect of Quetiapine on mania is more significant than Risperidone, which can effectively reduce the occurrence of adverse reactions, with high security.更多还原